Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics

被引：6

作者：

Wang, Yunxia ^{[1
]}

Liu, Xiaolin ^{[1
]}

Gong, Luyao ^{[1
]}

Ding, Weihong ^{[2
]}

Hao, Wenjing ^{[1
]}

Peng, Yeheng ^{[1
]}

Zhang, Jun ^{[1
]}

Cai, Weimin ^{[1
]}

Gao, Yuan ^{[1
]}

机构：

[1] Fudan Univ, Sch Pharm, Shanghai, Peoples R China

[2] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2023年 / 180卷 / 23期

基金：

中国国家自然科学基金;

关键词：

biomarkers; drug resistance; renal cell carcinoma; sunitinib; treatment strategies; CONCISE GUIDE; MULTIDRUG-RESISTANCE; KINASE INHIBITORS; TUMOR PROGRESSION; EXPRESSION; PROTEIN; CANCER; POLYMORPHISMS; EFFICACY; THERAPY;

D O I：

10.1111/bph.16252

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sunitinib is the first-line drug for renal cell carcinoma (RCC) treatment. However, patients who received sunitinib treatment will ultimately develop drug resistance after 6-15 months, creating a huge obstacle to the current treatment of renal cell carcinoma. Therefore, it is urgent to clarify the mechanisms of sunitinib resistance and develop new strategies to overcome it. In this review, the mechanisms of sunitinib resistance in renal cell carcinoma have been summarized based on five topics: activation of bypass or alternative pathway, inadequate drug accumulation, tumour microenvironment, metabolic reprogramming and epigenetic regulation. Furthermore, present and potential biomarkers, as well as potential treatment strategies for overcoming sunitinib resistance in renal cell carcinoma, are also covered.

引用

页码：2937 / 2955

页数：19

共 50 条

[31] RADIOGRAPHIC RESPONSE ASSOCIATED TO SUNITINIB RECHALLENGE IN METASTATIC RENAL CELL CARCINOMA
Buonerba, Carlo
Federico, Piera
Puglia, Livio
Bosso, Davide
Policastro, Tania
Izzo, Michela
De Placido, Sabino
Perdona, Sisto
Altieri, Vincenzo
De Cobelli, Ottavio
Bottero, Danilo
Ferro, Matteo
Di Lorenzo, Giuseppe
ANTICANCER RESEARCH, 2014, 34 (05) : 2614 - 2615
[32] Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma
Choi, Se Woong
Lee, Jeong Min
Kim, Dong Gyun
Noh, Myung Hwan
KOREAN JOURNAL OF GASTROENTEROLOGY, 2020, 75 (02): : 103 - 107
[33] Sunitinib-associated hypothyroidism in patients with metastatic renal cell carcinoma
Jagdev, Satinder
Hayward, Kate
Sim, Sheryl
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
[34] Sunitinib therapy in renal cell carcinoma
O'Brien, Matthew F.
Russo, Paul
Motzer, Robert J.
BJU INTERNATIONAL, 2008, 101 (11) : 1339 - 1342
[35] Sorafenib and sunitinib in renal cell carcinoma
Stein, Mark N.
Flaherty, Keith T.
CLINICAL CANCER RESEARCH, 2007, 13 (13) : 3765 - 3770
[36] Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC)
Armesto, Maria
Marquez, Maitane
Arestin, Maria
Errarte, Peio
Rubio, Ane
Manterola, Lorea
Lopez, Jose, I
Lawrie, Charles H.
CANCERS, 2021, 13 (17)
[37] Intrinsic resistance to sunitinib in clear cell renal cell carcinoma: A gene expression analysis
Reig, O.
Marin-Aguilera, M.
Lozano, J. J.
Gonzalez, B.
Mallofre, C.
Campayo, M.
Gascon, P.
Mellado, B.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : S167 - S167
[38] Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro
Ghosh, Susmita
Garige, Mamatha
Haggerty, Patrick R.
Norris, Alexis
Chou, Chao-Kai
Wu, Wells W.
Shen, Rong-Fong
Sourbier, Carole
CELL CYCLE, 2024, 23 (01) : 43 - 55
[39] Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities
Mahmoud, Ahmed M.
Nabavizadeh, Reza
Rodrigues Pessoa, Rodrigo
Garg, Ishita
Orme, Jacob
Costello, Brian A.
Cheville, John
Lucien, Fabrice
ONCOLOGIST, 2023, : 297 - 308
[40] Blocking stanniocalcin 2 reduces sunitinib resistance in clear cell renal cell carcinoma
Qin, Zhen-Qian
Li, Kong-Dong
Chu, He-Zhen
Yuan, Xue-Feng
Shi, Hai-Feng
Gu, Jie
Xie, Yi-Min
NEOPLASMA, 2022, 69 (01) : 145 - 154

← 1 2 3 4 5 →